Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis

被引：6

作者：

Haeussler, Katrin ^{[1
]}

Wang, Xuan ^{[2
]}

Winfree, Katherine B. ^{[3
]}

D'yachkova, Yulia ^{[4
]}

Traore, Sory ^{[5
]}

Puri, Tarun ^{[6
]}

Thom, Howard ^{[7
]}

Papagiannopoulos, Christos ^{[2
]}

Nassim, Maria ^{[1
]}

Taipale, Kaisa ^{[8
]}

机构：

[1] ICON Plc, D-81829 Munich, Germany

[2] ICON Plc, S-11121 Stockholm, Sweden

[3] Eli Lilly & Co, Indianapolis, IN 46285 USA

[4] Eli Lilly GmbH, Vienna, Austria

[5] Eli Lilly & Co, Arlington Sq, Basingstoke, Hants, England

[6] Eli Lilly & Co India Pvt Ltd, Gurgaon, India

[7] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol, Avon, England

[8] Oy Eli Lilly Finland Ab, Helsinki, Finland

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 16期

关键词：

EGFR positive; network meta-analysis; non-small-cell lung cancer; progression-free survival; systematic literature review; tyrosine kinase inhibitors; LONG-TERM RESPONDERS; RANDOMIZED PHASE-II; PLUS NSCLC ANALYSIS; QUALITY-OF-LIFE; GEFITINIB MAINTENANCE THERAPY; PATIENT-REPORTED OUTCOMES; RECEPTOR GENE-MUTATIONS; OPEN-LABEL; ASIAN PATIENTS; JAPANESE PATIENTS;

D O I：

10.2217/fon-2021-0885

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. Methods: In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. Results: For progression-free survival (PFS), ramucirumab + erlotinib was comparable to osimertinib and dacomitinib in the primary analysis. Conclusion: The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with EGFRm(+) advanced NSCLC. Registration information: PROSPERO ID:

引用

页码：2007 / 2028

页数：22

共 105 条

[1] An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer [J].

Ahmadzada, Tamkin ;

Kao, Steven ;

Reid, Glen ;

Boyer, Michael ;

Mahar, Annabelle ;

Cooper, Wendy A. .

JOURNAL OF CLINICAL MEDICINE, 2018, 7 (06)

[2]

[Anonymous], 2020, NCCN Clinical Practice Guidelines in Oncology: Survivorship

[3] Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis [J].

Buonerba, Carlo ;

Iaccarino, Simona ;

Dolce, Pasquale ;

Pagliuca, Martina ;

Izzo, Michela ;

Scafuri, Luca ;

Costabile, Ferdinando ;

Riccio, Vittorio ;

Ribera, Dario ;

Mucci, Brigitta ;

Carrano, Simone ;

Picozzi, Fernanda ;

Bosso, Davide ;

Formisano, Luigi ;

Bianco, Roberto ;

De Placido, Sabino ;

Di Lorenzo, Giuseppe .

CANCERS, 2019, 11 (09)

[4] Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group). [J].

Campelo, Rosario Garcia ;

Rodriguez, Oscar Gerardo Arrieta ;

Massuti, Bartomeu ;

Rodriguez-Abreu, Delvys ;

Granados, Ana Laura Ortega ;

Majem, Margarita ;

Vicente, David ;

Lianes, Pilar ;

Bosch-Barrera, Joaquim ;

Insa, Amelia ;

Domine, Manuel ;

Reguart, Noemi ;

Guirado, Maria ;

Sala, Maria Angeles ;

Vazquez-Estevez, Sergio ;

Caro, Reyes Bernabe ;

Drozdowskyj, Ana ;

Verdu, Ana ;

Karachaliou, Niki ;

Rosell, Rafael .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[5] Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [J].

Cheng, Ying ;

Murakami, Haruyasu ;

Yang, Pan-Chyr ;

He, Jianxing ;

Nakagawa, Kazuhiko ;

Kang, Jin Hyoung ;

Kim, Joo-Hang ;

Wang, Xin ;

Enatsu, Sotaro ;

Puri, Tarun ;

Orlando, Mauro ;

Yang, James Chih-Hsin .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) :3258-+

[6] Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset [J].

Cho, Byoung Chul ;

Chewaskulyong, Busayamas ;

Lee, Ki Hyeong ;

Dechaphunkul, Arunee ;

Sriuranpong, Virote ;

Imamura, Fumio ;

Nogami, Naoyuki ;

Kurata, Takayasu ;

Okamoto, Isamu ;

Zhou, Caicun ;

Cheng, Ying ;

Cho, Eun Kyung ;

Voon, Pei Jye ;

Lee, Jong-Seok ;

Mann, Helen ;

Saggese, Matilde ;

Reungwetwattana, Thanyanan ;

Ramalingam, Suresh S. ;

Ohe, Yuichiro .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) :99-106

[7]

Corral J., 2017, ANN ONCOL, V28, piii34

[8]

Cortot A., 2019, J CLIN ONCOL C, V37

[9]

Cortot AB, 2019, J CLIN ONCOL, V37

[10] Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer [J].

Di Maio, Massimo ;

Leighl, Natasha B. ;

Gallo, Ciro ;

Feld, Ronald ;

Ciardiello, Fortunato ;

Butts, Charles ;

Maione, Paolo ;

Gebbia, Vittorio ;

Morgillo, Floriana ;

Wierzbicki, Rafal ;

Favaretto, Adolfo ;

Alam, Yasmin ;

Cinieri, Saverio ;

Siena, Salvatore ;

Bianco, Roberto ;

Riccardi, Ferdinando ;

Spatafora, Mario ;

Ravaioli, Alberto ;

Felletti, Raffaella ;

Fregoni, Vittorio ;

Genestreti, Giovenzio ;

Rossi, Antonio ;

Fregoni, Vittorio ;

Genestreti, Giovenzio ;

Rossi, Antonio ;

Mancuso, Gianfranco ;

Fasano, Morena ;

Morabito, Alessandro ;

Tsao, Ming Sound ;

Signoriello, Simona ;

Perrone, Francesco ;

Gridelli, Cesare .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) :1830-1844

← 1 2 3 4 5 6 7 8 9 10 →